摘要
目的:观察阿托伐他汀联合肾康注射液对慢性肾衰竭患者残余肾功能的保护作用。方法:将2015年3月至2016年6月肾内科收治的124例慢性肾衰竭(chronic renal failure,CRF)患者,随机分为对照组和观察组,每组62例。两组患者均给予常规治疗,包括低脂低蛋白、控制血压、调节血糖、营养补充、纠正贫血等及血液透析治疗。对照组患者在常规治疗基础上给予阿托伐他汀治疗,观察组在常规治疗基础上给予阿托伐他汀联合肾康注射液治疗。分别于治疗前后检测两组患者血肌酐(serum creatinine,Scr)、尿素氮(blood urea nitrogen,BUN)、24 h蛋白尿(urine protein,U-pro)、血浆C-反应蛋白(C-reactive protein,CRP)、残余肾功能(residual renal function,RRF)水平。结果:治疗前,两组Scr、BUN、U-pro、RRF、CRP等水平比较差异均无统计学意义(P>0.05);治疗后,两组Scr、BUN、U-pro、RRF、CRP水平均降低,与治疗前比较均具有统计学意义(P<0.05),且观察组的Scr、BUN、U-pro、CRP低于对照组(P<0.05);治疗后观察组RRF高于对照组(t=2.115,P=0.047)。结论:阿托伐他汀联合肾康注射液可明显抑制炎症反应、减少蛋白尿排出,有效维持CRF患者残余肾功能,效果显著,值得临床推广。
Objective： To observe the protective effects of atorvastatin combined with Shenkang injection on residual renal function in patients with chronic renal failure. Methods： 124 patients with chronic renal failure（ CRF） hospitalized in the Urology Department from March 2015 to June 2016 were randomly divided into the control group and the observation group,with 62 patients in each group. The patients in both groups were given conventional treatment including low-fat low-protein,blood pressure control,blood glucose regulation,nutritional supplements,correction of anemia and hemodialysis. The control group was further treated by atorvastatin while the observation group was further treated by atorvastatin combined with Shenkang injection,with the levels of serum creatinine（ Scr）,urea nitrogen（ BUN）,24 h proteinuria（ U-pro）,plasma C-reactive protein（ CRP） and residual renal function（ RRF） measured before and after treatment. Results： Before treatment,there were no significant differences in the levels of Scr,BUN,U-pro,RRF,CRP between the two groups（ P〈0. 05）. After treatment,the levels of Scr,BUN,U-pro,RRF and CRP in the two groups were significantly decreased（ P〈0. 05）,and these levels in the observation group decreased significantly than those in the control group（ P〈0. 05）. The RRF in the observation group increased obviously compared with the RRF before treatment,but the difference was not statistically significant（ P〉0. 05）. The RRF in the control group was lower than that before treatment,but the difference was not statistically significant（ P〈0. 05）. After treatment,the RRF in the observation group was significantly higher than that in the control group,and the difference was statistically significant（ t = 2. 115,P = 0. 047）. Conclusion： Atorvastatin combined with Shenkang injection can obviously inhibit the inflammatory reaction,reduce the excretion of proteinuria and effectively maintain the residual renal function in patients with CRF,worthy of clinical promotion.
出处
《包头医学院学报》
CAS
2017年第8期18-19,45,共3页
Journal of Baotou Medical College
关键词
阿托伐他汀
肾康注射液
慢性肾衰竭
残余肾功能
保护
Atorvastatin
Shenkang injection
Chronic renal failure
Residual renal function
Protection
